دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cancer, health-care backlogs, and the cost-of-living crisis
doi : 10.1016/S1470-2045(22)00302-3
Volume 23, Issue 6, June 2022, Page 691
Validating chemoimmunotherapy in small-cell lung cancer
Katherine E RSmithaAaron SMansfielda
COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties
Nicole MKudereraGary HLymanbcd
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer
GonzaloRecondoaLauraMezquitabcd
Personalised care for high-risk rectal cancer: does one size fit all?
Britt J PHupkensaStéphanie OBreukinkbcd
Awake craniotomy as a mandatory part of the armamentarium of surgical neuro-oncologists
Sandro MKriega
Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia
StefanoMolicaaDavid JohnAllsupab
Cancer in sub-Saharan Africa: the time to act is now
KatherineGourdaDavidCollingridgea
Rays of Hope: the IAEA ups its commitment to cancer care
Rafael MarianoGrossia
Cancer in sub-Saharan Africa: key research and action gaps
Sonali ElizabethJohnsonaFannyBaueraLara AbdelmunimIdrisb
African culture, traditional medicine, and cancer care
Peter BaiJamesabJohn BaptistAsiimwecdeJonWardleaAmos DeogratiusMwakafOssy Muganga JuliusKasilog
Religion, cancer, and sub-Saharan African health systems
JillOliviera
Preventing cancer and achieving optimal oncology outcomes in sub-Saharan Africa
IbrahimAbubakara
Preventing cancer and achieving optimal oncology outcomes in sub-Saharan Africa
Ulrich SSchulera
Abemaciclib for malignant pleural mesothelioma
ValerioNardoneaCamilloPortabRoccoGiannicolacPierpaoloCorrealecLucianoMuttide
Abemaciclib for malignant pleural mesothelioma – Authors' reply
Dean AFennellaNadaNusrata
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma
Guan-JiangHuangaZhi-JunFanaBiao-QingLua
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma
Chieh-MinLiuaJen-YuChengaYun-HsuanLinaChung-ShihChenaYu-MingWangabc
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma – Authors' reply
Ling-LongTangaCheng-LongHuangaJunMaa
The future of precise cancer chronotherapeutics
Pasquale FInnominatoabcAbdoulayeKarabouécdMohammedBouchahdacefgGeorg ABjarnasonhFrancis ALévibci
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma
LeiLiuaRuiLiaob
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors' reply
Darren Jun HaoTanaCheng HanNgaMark DMuthiahabRohitLoombacDaniel QHuangabc
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy
DavidBomzeaLucianoMuttibAdamGoldmancGalMarkeldTomerMeirsond
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
ThierryAndréaLuis ADiazJrbKai-KeenShiuc
NICE 2020 guideline for the management of colorectal cancer
JustinDaviesabCindyChewcNathanBromhamdPeterHoskinefNational Institute for Health and Care Excellence (NICE)
Economic crisis in Sri Lanka causing cancer drug shortage
ManjulikaDas
President Macron's re-election and cancer research and care in France
BarbaraCasassus
New United Arab Emirates representative joins WHO regional palliative care expert network
ManjulikaDas
New coalition to increase access to cancer medicines in LMICs
Talha KhanBurki
Oncology specialists' perspective on caring for patients with cancer during the early days of war in Kyiv, Ukraine
PhilippBarakataOleksandrStakhovskyibViacheslavKopetskyibMary CaitlinKingaCarolNierodaaVadimGushchina
Fidel Rubagumya—founder of Rwanda Cancer Relief
ElizabethGourd
Philippa Kibugu-Decuir—founder of Breast Cancer Initiative East Africa
ElizabethGourd
Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs
FreddieBrayPhDaD MaxwellParkinMDbc
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study
MilenaFoersterPhDaValerieMcCormackPhDaProfBenjamin OAndersonMDbPaulineBoucheronMDaAnnelleZietsmanMDcHerbertCubaschMDdMaureenJoffePhDeAngelicaAneleMDfShadrachOffiahMDgProfMosesGalukandeMDhProfGroesbeckParhamMDiLeeya FPinderMDjOphiraGinsburgMDaJoachimSchüzPhDaProfIsabeldos-Santos-SilvaMDkEva JKantelhardtMDl
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
ProfJieWangMDaProfCaicunZhouMDbProfWenxiuYaoPhDcProfQimingWangMDdXuhongMinBSeProfGongyanChenMDfProfXingxiangXuMDgProfXingyaLiMDhProfFeiXuMDiProfYongFangMDjProfRunxiangYangMMkProfGuohuaYuBSlProfYoulingGongPhDmProfJunZhaoMDnProfYunFanMDoProfQuanLiuMDpProfLejieCaoMDqProfYuYaoMDr…XiaojingZhang
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
Lennard Y WLeeDPhilab*ThomasStarkeyMScib*Maria CIonescuMScie*MartinLittleMResf*MichaelTilbyMBChBg*Arvind RTripathyMDg*Hayley SMckenziePhDh*YoussraAl-HajjidMatthewBarnardPhDeLizaBennyPhDeAlexanderBurnettFRCRijEmma LCattellPhDkJackieCharmanBSclJames JClarkMBBChirmSamKhanPhDnQamarGhafoorMBChBgGeorgeIllsleyBSceCatherineHarper-WynneMDo…ProfPeterJohnsonMDiabâ€
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Marjorie GZaudererMDaProfPeter WSzlosarekMDbSylvestreLe MoulecMDcProfSanjayPopatFRCPdPaulTaylorMBChBeDavidPlanchardMDfProfArnaudScherpereelMDgMariannaKoczywasMDhMartinForsterMDiProfRobert BCameronMDjTobiasPeikertMDkEvren KocabaÅŸArgonDVMlNeil RMichaudPhDlAttilaSzantoMDlJayYangPhDlYingxueChenPhDlVikramKansraPhDlShefaliAgarwalMDlProfDean AFennellPhDm
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
ProfRobertMotzerMDaProfCamilloPortaMDbcProfBorisAlekseevMDdProfSun YoungRhaMDeProfToni KChoueiriMDfMaria JoseMendez-VidalMDgProfSung-HooHongMDhProfAnilKapoorMDiJeffrey CGohMDjProfMasatoshiEtoMDkLeeBennettMSlJinyiWangMStatlJie JanicePanMPHmTodd LSaretskyMPHnRodolfo FPeriniMDnCixin StevenHePhDmKalgiModyMDmProfDavidCellaPhDo
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung ChulChoMDaDelvys RodriguezAbreuMDbMaenHusseinMDcManuelCoboMDdAnjan JPatelMDeNevenaSecenMDfKi HyeongLeeMDgBartomeuMassutiMDhSandrineHiretMDiJames Chih HsinYangMDjFabriceBarlesiMDklDae HoLeeMDmLuis PazAresMDnRobert WHsiehMDoNamrata SPatilPhDoPatrickTwomeyMDoXiaoyingYangPhDoRaymondMengMDoMelissa LJohnsonMDp
Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study
Amy CLordFRCSabAlisonCorrFRCRcAnuradhaChandramohanFRCRdNicolaHodgesFRCSacEdwardPringFRCScCliziaAiro-FarullaFRCSbBrendanMoranFRCSbJohn TJenkinsFRCScFrancescoDi FabioFRCSbProfGinaBrownFRCRa
Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study
Jasper K WGerritsenMDaRosa HZwarthoedBScbJohn LKilgallonBSccNoah LNawabiBSccCharissa A CJessurunMDcGeorgesVersyckMDdKoen PPruijnBScbFleur LFisherBScbEmmaLarivièreMScdLienSolieMScdRania AMekaryPhDcefDjaina DSatoerPhDaJoost WSchoutenMDaEelke MBosPhDaAlfredKloetMDbRishiNandoe TewariePhDbTimothy RSmithPhDcProfClemens M FDirvenPhDa…ProfArnaud J P EVincentPhDaâ€
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
ProfArnon PKaterMDaMark-DavidLevinMDdJulieDuboisMDaSabinaKerstingMDeLisbethEnggaardMDfGerrit JVeldhuisMDgRogierMousMDhClemens H MMellinkPhDbAnne-Marie Fvan der Kevie-KersemaekersPhDbJohan ADobberIngcChristian BPoulsenMDiProfHenrikFrederiksenMDjAnnJanssensMDkIdaSchjødtMDlEllen CDompelingMDmJuhaRantiMDnChristianBrieghelMDlMattiasMattssonMDo…Carsten UNiemannMDl
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
ProfWilfredNgwaPhDabdBeatrice WAddaiMDeProfIsaacAdewoleMDfVictoriaAinsworthBScgJamesAlaroPhDhProfOlusegun IAlatiseMDiZipporahAliMDjProfBenjamin OAndersonMDkabProfRoseAnorluMDlStephenAveryPhDmPreboBarangoMDnNoellaBihBScoProfChristopher MBoothMDpProfOtis WBrawleyMDbcJean-MarieDangouMDnProfLynetteDennyMDraaaJenniferDentMBAsShekinah N CElmoreMDt…ProfDavidKerrMDaz
